Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.

Authors:
Shintaro Hirata
Shintaro Hirata
School of Medicine
Japan
Satoshi Kubo
Satoshi Kubo
School of Medicine
Japan
Yoshiya Tanaka
Yoshiya Tanaka
University of Occupational and Environmental Health
Japan

Clin Exp Rheumatol 2018 May-Jun;36(3):462-470. Epub 2018 Feb 14.

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Hiroshima, Japan.

Objectives: This prospective study aimed to use serological biomarkers for evaluation of, connective tissue turnover, in a population of 149 Japanese patients with rheumatoid arthritis (RA). It was aimed to investigate how the connective tissue was affected by treatment at follow-up after 1 year (+/- 6 weeks) with either methotrexate (n=23) alone, or in combination with: adalimumab (n=49), tofacitinib (n=27) or tocilizumab (n=50).

Methods: Clinical characteristics were collected and connective tissue turnover, was evaluated by 4 serological biomarkers: C1M and C3M reflect degradation of types I and III collagen in interstitial tissue; C4M, reflecting degraded type IV collagen of the basement membranes; and CRPM, a marker of degraded C-reactive protein. Evaluated biomarker levels were measured at baseline and at follow-up. Levels were compared to the reference levels of healthy individuals.

Results: The four evaluated biomarkers were all elevated at baseline in patients with RA compared to healthy individuals. The biomarkers were higher in RA patients compared to healthy individuals at baseline and they were all significantly correlated with disease activity score of 28 joint (DAS28) (p<0.0001). The biomarker levels were all significantly decreased in all four patient groups at follow-up in all of the four treatment groups.

Conclusions: Rheumatoid joint inflammation elicits enhanced turnover of major collagen constituents of the synovial membrane and this abnormal pathway may be implicated in erosive progression. Evaluations of the applied biomarkers: C1M, C3M, C4M and CRPM, indicate that the pathologically enhanced tissue turnover was attenuated, by all of the four studied treatments.
July 2018
12 Reads

Publication Analysis

Top Keywords

connective tissue
12
serological biomarkers
8
japanese patients
8
prospective study
8
rheumatoid arthritis
8
tissue turnover
8
healthy individuals
8
compared healthy
8
patients compared
8
patients rheumatoid
8
149 japanese
8
patients
5
evaluated biomarker
4
characteristics collected
4
baseline patients
4
follow-up levels
4
clinical characteristics
4
biomarker levels
4
turnover evaluated
4
protein evaluated
4

Similar Publications

IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.

Clin Exp Rheumatol 2018 Jul-Aug;36(4):568-574. Epub 2018 Jan 31.

Nordic Bioscience, Herlev, Denmark.

Objectives: The objective of this study was to examine the tissue degradation in response to anti-IL6 receptor treatment in rheumatoid arthritis (RA) patients which are anti-TNF-α inadequate responders.

Methods: RADIATE was a randomised, double-blinded, placebo-controlled, parallel-group, phase III trial. RA patients with previous inadequate response to anti-TNFα therapy (n=299) were randomly assigned to tocilizumab 4 or 8 mg/kg with methotrexate (10-25 mg weekly) or placebo with methotrexate. Read More

View Article
September 2018

Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis.

PLoS One 2016 28;11(3):e0149329. Epub 2016 Mar 28.

Nordic Bioscience, Herlev, Denmark.

Objective: Tissue destruction in rheumatoid arthritis (RA) is predominantly mediated by matrix metalloproteinases (MMPs), thereby generating protein fragments. Previous studies have revealed that these fragments include MMP-mediated collagen type I, II, and III degradation, citrullinated and MMP-degraded vimentin and MMP degraded C-reactive protein. We evaluated if biomarkers measuring serum levels of specific sequences of the mentioned fragments would provide further information of diagnostic and/or prognostic processes in early arthritis. Read More

View Article
August 2016

Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study.

Semin Arthritis Rheum 2014 Feb 6;43(4):470-8. Epub 2013 Aug 6.

Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark.

Objective: We investigated the effects of tocilizumab (TCZ) on joint tissue remodeling in patients with moderate to severely active RA by measuring tissue-specific biomarker.

Methods: The LITHE biomarker study (n = 740) was a phase III study of 4- and 8-mg/kg TCZ in combination with MTX. Early response was evaluated at week 16 as ±20% improvement in swollen/tender joint counts; and ACR50 was evaluated at week 52. Read More

View Article
February 2014

Serological identification of fast progressors of structural damage with rheumatoid arthritis.

Arthritis Res Ther 2013 Aug 14;15(4):R86. Epub 2013 Aug 14.

Introduction: Rheumatoid arthritis (RA) patients with structural progression are in most need of immediate treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-inflammatory treatment with tocilizumab (TCZ). Read More

View Article
August 2013